

# SCN5A variant that blocks fibroblast growth factor homologous factor regulation causes human arrhythmia

Hassan Musa<sup>a,b</sup>, Crystal F. Kline<sup>a,b</sup>, Amy C. Sturm<sup>a,c</sup>, Nathaniel Murphy<sup>a,b</sup>, Sara Adelman<sup>a,b</sup>, Chaojian Wang<sup>d</sup>, Haidun Yan<sup>d</sup>, Benjamin L. Johnson<sup>a,b</sup>, Thomas A. Csepe<sup>a,b</sup>, Ahmet Kilic<sup>a,e</sup>, Robert S. D. Higgins<sup>a,e</sup>, Paul M. L. Janssen<sup>a,b,f</sup>, Vadim V. Fedorov<sup>a,b</sup>, Raul Weiss<sup>a,f</sup>, Christina Salazar<sup>a,f</sup>, Thomas J. Hund<sup>a,f,g</sup>, Geoffrey S. Pitt<sup>d</sup>, and Peter J. Mohler<sup>a,b,f,1</sup>

<sup>a</sup>Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210; <sup>b</sup>Department of Physiology & Cell Biology, The Ohio State University Wexner Medical Center, Columbus, OH 43210; <sup>c</sup>Department of Internal Medicine, Division of Human Genetics, The Ohio State University Wexner Medical Center, Columbus, OH 43210; <sup>d</sup>Department of Medicine and Ion Channel Research Unit, Duke University Medical Center, Durham, NC 27709; <sup>e</sup>Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210; <sup>f</sup>Department of Internal Medicine, Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210; and <sup>g</sup>Department of Biomedical Engineering College of Engineering, The Ohio State University, Columbus, OH 43210

Edited by Louis J. Ptáček, University of California, San Francisco, CA, and approved August 31, 2015 (received for review August 20, 2015)

**Na<sub>v</sub> channels are essential for metazoan membrane depolarization, and Na<sub>v</sub> channel dysfunction is directly linked with epilepsy, ataxia, pain, arrhythmia, myotonia, and irritable bowel syndrome. Human Na<sub>v</sub> channelopathies are primarily caused by variants that directly affect Na<sub>v</sub> channel permeability or gating. However, a new class of human Na<sub>v</sub> channelopathies has emerged based on channel variants that alter regulation by intracellular signaling or cytoskeletal proteins. Fibroblast growth factor homologous factors (FHF) are a family of intracellular signaling proteins linked with Na<sub>v</sub> channel regulation in neurons and myocytes. However, to date, there is surprisingly little evidence linking Na<sub>v</sub> channel gene variants with FHF and human disease. Here, we provide, to our knowledge, the first evidence that mutations in *SCN5A* (encodes primary cardiac Na<sub>v</sub> channel Na<sub>v</sub>1.5) that alter FHF binding result in human cardiovascular disease. We describe a five-generation kindred with a history of atrial and ventricular arrhythmias, cardiac arrest, and sudden cardiac death. Affected family members harbor a novel *SCN5A* variant resulting in p.H1849R. p.H1849R is localized in the central binding core on Na<sub>v</sub>1.5 for FHF. Consistent with these data, Na<sub>v</sub>1.5 p.H1849R affected interaction with FHF. Further, electrophysiological analysis identified Na<sub>v</sub>1.5 p.H1849R as a gain-of-function for I<sub>Na</sub> by altering steady-state inactivation and slowing the rate of Na<sub>v</sub>1.5 inactivation. In line with these data and consistent with human cardiac phenotypes, myocytes expressing Na<sub>v</sub>1.5 p.H1849R displayed prolonged action potential duration and arrhythmogenic afterdepolarizations. Together, these findings identify a previously unexplored mechanism for human Na<sub>v</sub> channelopathy based on altered Na<sub>v</sub>1.5 association with FHF proteins.**

ion channel | channelopathy | atrial fibrillation | Nav1.5 | FHF

Encoded by 10 different genes, Na<sub>v</sub> channel  $\alpha$ -subunits regulate excitable membrane depolarization and are therefore central to metazoan physiology (1). Na<sub>v</sub> channel function is critical for neuronal firing and communication (1, 2), cardiac excitation–contraction coupling (3), and skeletal and intestinal function (4, 5). The impact of Na<sub>v</sub> channel function for human biology has been elegantly defined by nearly two decades of studies directly linking Na<sub>v</sub> channel gene variants with human disease. To date, the field of human Na<sub>v</sub> channelopathies has exploded to include wide spectrums of neurological [epilepsy (1), pain (6), ataxia (7)] and cardiovascular diseases (8) as well as myotonia congenital (9) and even irritable bowel syndrome (5). Though the majority of these diseases are based on gene variants in Na<sub>v</sub> channel transmembrane segments that affect the channel pore or channel gating (10), a new paradigm for Na<sub>v</sub> channelopathies has emerged based on variants that alter association of Na<sub>v</sub> channels with essential regulatory proteins. To date, human Na<sub>v</sub> channel gene variants linked with neurological and cardiovascular disease have not only provided new insight on the pathophysiology

of excitable cell disease, but also identified and/or validated key in vivo Na<sub>v</sub> channel regulatory pathways [syntrophin (11), ankyrin-G (12, 13), Na<sub>v</sub>  $\beta$ 1 (14), calmodulin (15), protein kinase A (16), and CaMKII $\delta$  (17, 18)]. However, in many cases, whereas animal and cellular findings may strongly support the role of regulatory proteins for human Na<sub>v</sub> channel function, human variants that may serve to validate the association have remained elusive, likely due to redundancy of signaling pathways or extreme severity of the disease.

Identified in the retina nearly two decades ago, fibroblast growth factor homologous factors (FHF; FGF11–14) are a family of signaling proteins with key roles in ion channel regulation (19). Distinct from canonical FGFs that are secreted and bind to extracellular FGF receptors, FGF11–14 lack signal sequences and thus regulate intracellular targets. Currently, Na<sub>v</sub> channels are the most characterized FHF target (20–22), and recent structural data mapped the FHF binding site to the Na<sub>v</sub> channel C terminus (23, 24). Notably, FHF display multiple roles in Na<sub>v</sub> channel regulation, including expression, trafficking, and channel gating. However, each FHF appears to show unique regulatory roles for Na<sub>v</sub> channel regulation that are cell type and Na<sub>v</sub> channel isoform dependent. Though FHF signaling is complex, the roles of FHF

## Significance

**Cardiovascular disease remains the leading cause of mortality in the United States, and cardiac arrhythmia underlies the majority of these deaths. Here, we report a new mechanism for congenital human cardiac arrhythmia due to defects in the regulation of the primary cardiac Na<sub>v</sub> channel, Na<sub>v</sub>1.5 (*SCN5A*), by a family of signaling molecules termed fibroblast growth factor homologous factors (FHF). Individuals harboring *SCN5A* variants that affect Na<sub>v</sub>1.5/FHF interactions display atrial and ventricular phenotypes, syncope, and sudden cardiac death. The human variant results in aberrant Na<sub>v</sub>1.5 inactivation, causing prolonged action potential duration and afterdepolarizations in murine myocytes, thereby providing a rationale for the human arrhythmia.**

Author contributions: H.M., C.F.K., A.C.S., N.M., P.M.L.J., V.V.F., R.W., C.S., T.J.H., G.S.P., and P.J.M. designed research; H.M., C.F.K., A.C.S., N.M., S.A., C.W., H.Y., B.L.J., T.A.C., V.V.F., R.W., C.S., and G.S.P. performed research; H.M., C.F.K., A.C.S., N.M., S.A., C.W., H.Y., T.A.C., A.K., R.S.D.H., P.M.L.J., V.V.F., R.W., C.S., T.J.H., and G.S.P. contributed new reagents/analytic tools; H.M., C.F.K., A.C.S., N.M., S.A., C.W., H.Y., B.L.J., P.M.L.J., V.V.F., R.W., C.S., T.J.H., G.S.P., and P.J.M. analyzed data; and H.M., C.F.K., A.C.S., S.A., T.J.H., G.S.P., and P.J.M. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

<sup>1</sup>To whom correspondence should be addressed. Email: peter.mohler@osumc.edu.

This article contains supporting information online at [www.pnas.org/lookup/suppl/doi:10.1073/pnas.1516430112/-DCSupplemental](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1516430112/-DCSupplemental).

in vertebrate physiology are clearly illustrated by dysfunction of FHF in human disease. To date, FHF loci have been linked with spinocerebellar ataxia 27, X-linked mental retardation, and cardiac arrhythmia (25–27). In animals, FHF deficiency results in severe neurological phenotypes associated with altered  $\text{Na}_v$  channel function (28). Despite the overwhelming biochemical, functional, and *in vivo* animal data linking  $\text{Na}_v$  channels and FHF proteins, and in contrast to many other  $\text{Na}_v$  channel regulatory pathways, there are surprisingly little data linking human  $\text{Na}_v$  channel variants with FHF in any disease.


Here we provide, to our knowledge, the first evidence that human  $\text{Na}_v$  channel gene variants that alter FHF binding result in potentially fatal human disease. We describe a five-generation kindred with a history of atrial and ventricular arrhythmias, cardiac arrest, and sudden cardiac death. Genetic testing revealed a *SCN5A* variant, resulting in p.H1849R, in affected family members. The identified *SCN5A* variant p.H1849R is novel and located at a site in the  $\text{Na}_v1.5$  C-terminal domain identified to associate with FHF. Notably, the human p.H1849R variant markedly altered interaction with FHF, and functional analysis of the variant identified  $\text{Na}_v1.5$  p.H1849R as a gain-of-function variant. Further, consistent with LQT3 phenotypes observed in the family, expression of this variant resulted in prolonged action potential duration and arrhythmogenic afterdepolarizations. Together, our findings define a previously unidentified mechanism for human  $\text{Na}_v$  channelopathies based on loss of  $\text{Na}_v1.5$  association with FHF proteins and further confirm the critical link between these intracellular proteins and  $\text{Na}_v$  channels in excitable cells.

## Results


**$\text{Na}_v1.5$  Variant p.H1849R Associates with LQT, Atrial Fibrillation, Ventricular Tachycardia, and Sudden Cardiac Arrest.** We identified a previously uncharacterized *SCN5A* variant associated with atrial fibrillation (AF), long QT, and sudden cardiac arrest. The proband is a 27-y-old male who suffered sudden cardiac arrest at work while moving boxes. Upon resuscitation with CPR and automated external defibrillator (AED) shock, initial ECG recordings presented episodes of AF, evident by the lack of P-waves and a varying R–R interval, accompanied by prevalent premature ventricular contractions

(PVCs; Fig. 1A, white arrows). Subsequent interrogations revealed a prolonged QT interval, with a corrected QT ( $\text{QT}_c$ ) up to 496 ms (sinus rhythm), augmented by ST segment changes and episodes of AF. Procainamide challenge of the proband was negative for Brugada (BrS) ECG pattern, and did not demonstrate J-point elevation or QRS prolongation. Serial echocardiograms were unremarkable in terms of ventricular function and atrial and ventricular dimensions. A diagnosis of LQT3 was made after serial rest ECGs disclosed persistent  $\text{QT}_c$  prolongation. Based on phenotypes and witnessed arrest, the proband was implanted with dual chamber implantable cardioverter defibrillator (ICD). The ICD has appropriately fired multiple times in response to sustained ventricular tachycardia/fibrillation (Fig. 1B). Notably, several family members have presented cardiac abnormalities coincident with a family history of sudden cardiac death (SCD; Fig. 1C). Due to the high suspicion for primary arrhythmia disease and documented family history of SCD, the proband underwent targeted genetic testing for identified arrhythmia genes (*KCNQ1*, *KCNH2*, *SCN5A*, *ANK2*, *KCNE1*, *KCNE2*, *KCNJ2*, *CACNA1C*, *CAV3*, *SCN4B*, *AKAP9*, and *SNTA1*). No known disease-associated variants were identified. However, secondary testing identified a heterozygous A > G nucleotide substitution in exon 28 of the *SCN5A* gene, producing a histidine-to-arginine change in  $\text{Na}_v1.5$ , the primary cardiac  $\text{Na}_v$  channel (Fig. 1D and E;  $\text{Na}_v1.5$  p.H1849R). The variant was not previously identified as disease causing, and has not been observed in the general population (minor allele frequency was 0.0 in ExAC and ClinVar). Follow-up ECGs consistently demonstrated periods of prolonged  $\text{QT}_c$ , mild ST segment changes, AF, and PVCs.

Cascade screening showed that the proband's mother and sister harbored the  $\text{Na}_v1.5$  p.H1849R variant (Fig. 1C). ECGs from the proband's mother show borderline prolonged  $\text{QT}_c$  ( $\text{QT}_c > 460$  ms) with slight ST changes following exertion. Results from an implantable loop recorder (ILR) document several episodes of nonsustained AF with atrial and ventricular pacing, and a rate-dependent bundle branch block. Succeeding interrogations of the ILR demonstrated continued periods of AF, summing in a visit to the emergency room for a 2-h period of recorded symptomatic AF. Patient's sister reported a history of syncope, palpitations, and chest tightness following caffeine. Episodes of supraventricular



**Fig. 1.** Human  $\text{Na}_v1.5$  H1849R variant associates with LQT and atrial fibrillation. (A) ECG records taken following resuscitation of a 27-y-old male experiencing sudden cardiac arrest. ECGs demonstrate atrial fibrillation and premature ventricular contractions (white arrows). (B) Malignant ventricular arrhythmia in proband requiring ICD discharge (note "S"). (C) Family pedigree of the proband (arrow) denoting members harboring the H1849R variant (+ symbol) and associated phenotypes. LQT, long QT, SCA, sudden cardiac arrest. (D) Chromatograms denoting the nucleotide change (A > G) resulting in a histidine-to-arginine change at amino acid position 1849 of  $\text{Na}_v1.5$  in proband. (E) Membrane topology of  $\text{Na}_v1.5$  protein denoting location the H1849R variant. (F)  $\text{Na}_v1.5$  H1849R is highly conserved across species.




**Fig. 2.** Human Na<sub>v</sub>1.5 p.H1849R variant blocks association with FHF proteins. (A) Schematic of Na<sub>v</sub>1.5 denoting FHF binding domain in red. (B) Interaction surfaces of FGF13 and Na<sub>v</sub>1.5, denoting the critical Arg57 on FGF13 (blue) and its interaction pocket anchored by His1849 (yellow). (C) Na<sub>v</sub>1.5 Ig coimmunoprecipitated FGF13 from detergent-soluble lysates of murine heart. (D) Conversely, FGF13 Ig coimmunoprecipitated Na<sub>v</sub>1.5 from detergent-soluble lysates of murine heart. (E) Immobilized GST-Na<sub>v</sub>1.5 C terminus (CT) associated with FGF13 from detergent-soluble lysates of murine hearts. In contrast, p.H1849R CT did not demonstrate significant binding. No interaction was observed between FGF13 and GST alone. (F) <sup>35</sup>S-labeled FGF12, 13, and 14 directly associate with GST-Na<sub>v</sub>1.5 CT but not GST-Na<sub>v</sub>1.5 p.H1849R. (G and H) Isothermal titration calorimetry data demonstrated a 10<sup>2</sup>-fold decrease in binding affinity for FGF13 to the H1849R C-terminal domain (CTD) relative to WT CTD (K<sub>d</sub> = 1.88 ± 0.11 μM and 16.6 ± 0.7 nM, respectively; n = 3, P < 0.05). (I) Qualitative rendering of binding affinity of Na<sub>v</sub>1.5 CT H1849R relative to WT Na<sub>v</sub>1.5 CT.

and ventricular ectopy were recorded on a Holter monitor, and subsequently an ILR was placed for future interrogation. After positive genetic screening in the proband's sister, further screening for the proband's niece and nephew was indicated, and consent was given for testing. Genetic screening of the niece (5 y) was positive for the p.H1849R variant, and follow-up was initiated for electrophysiology study testing. A diagnosis of LQT3 was made after serial-rest ECGs disclosed persistent QTc prolongation (QTc 471 ms). Intermittent late-peaking T waves were also appreciated. Other significant family history included the proband's maternal

grandfather who had SCD in his sleep at the age of 28, and a maternal paternal great grandfather who had SCD in his sleep at the age of 52. No autopsies were performed on these individuals, and no DNA is available for evaluation.

**Na<sub>v</sub>1.5 p.H1849R Alters Association with FHFs.** p.H1849 is located in the cytoplasmic C terminus of Na<sub>v</sub>1.5 (Na<sub>v</sub>1.5 CT) and conserved across species (Fig. 1 E and F). This specific residue was previously identified as forming part of the binding pocket for FHFs (23). A rendering of the interaction surfaces for FGF13 and the Na<sub>v</sub>1.5




**Fig. 3.** Nav1.5 p.H1849R results in gain of function. (A)  $I_{Na}$  elicited from Nav1.5 p.H1849R-expressing myocytes (blue,  $n = 8$ ) displayed significantly larger  $I_{Na}$  density relative to cells expressing WT Nav1.5 (black,  $n = 7$ ;  $P < 0.05$ ). I-V relationship for cells silenced for endogenous Nav1.5, but untransfected, shown in red ( $n = 5$ ). (B) Boltzmann fits of the voltage-dependent inactivation (dashed lines) of the p.H1849R channels (blue circles) demonstrated a depolarizing shift in the  $V_{1/2}$  relative to WT (black circles;  $-101.2$  vs.  $-107.9$  mV;  $P < 0.05$ ). Boltzmann fits of the voltage-dependent activation profile (solid blue and black lines) showed similar  $V_{1/2}$  values ( $-61.9$  vs.  $-62.4$  mV for WT and p.H1849R, respectively;  $P = N.S.$ ).  $R^2$  values for all fits  $> 0.99$ . (C)  $I_{Na}$  elicited from Nav1.5 p.H1849R and FGF12 expressed in HEK293 cells (blue,  $n = 14$ ) displayed significantly larger  $I_{Na}$  density relative to currents from cells expressing WT Nav1.5 (black,  $n = 11$ ;  $P < 0.01$  for test voltages as indicated). (D) Boltzmann fits of the steady-state voltage-dependent inactivation of the p.H1849R channels expressed with FGF12 (blue triangles,  $n = 13$ ) demonstrated a depolarizing shift in the  $V_{1/2}$  relative to WT expressed with FGF12 (black circles,  $n = 12$ ;  $-67.7$  vs.  $-76.2$  mV;  $*P < 0.01$ ). (E) Boltzmann fits of the voltage-dependent activation profile show similar  $V_{1/2}$  values [ $-56.0$  vs.  $-55.7$  mV for WT ( $n = 11$ ) and p.H1849R ( $n = 14$ ), respectively;  $P = N.S.$ ].  $V_m$  in D and mV in E. (F) Scaled exemplar traces at a test potential of  $-40$  mV and one-exponential fits of the decay phases for the p.H1849R channels expressed with FGF12 (blue solid line and dashed line, respectively) and for the WT Nav1.5 channels expressed with (black solid line and dashed line, respectively). (G) Decay time,  $\tau$ , of the fits as in H ( $n = 28$  for p.H1849R and  $n = 21$  for WT;  $*P < 0.01$ ).

CT demonstrates a critical association between FGF13 Arg57 with its interaction pocket anchored by residue H1849 on the Nav1.5 CT (Fig. 2A and B). We tested the impact of p.H1849R on Nav1.5/FHF interactions. Coimmunoprecipitation experiments using detergent-soluble lysates from mouse heart confirmed interaction of Nav1.5 with FGF13 (Fig. 2C and D). Further, pull-down experiments from detergent-soluble lysates from mouse heart demonstrated direct association of GST-Nav1.5 C terminus with FGF13 (Fig. 2E). The p.H1849R variant altered the interaction with FHFs. First, in the context of a GST-Nav1.5 CT fusion protein, the variant reduced binding for FGF13 from detergent-soluble lysates from mouse heart (Fig. 2E). We observed no binding of GST alone for FGF13. Second, in vitro binding assays demonstrated similar results with all FHFs: radiolabeled FGF12, FGF13, and FGF14 all showed reduced interaction with GST-Nav1.5 CT harboring the p.H1849R variant or GST alone (Fig. 2F). We quantified the impact of the Nav1.5 p.H1849R variant on FHF binding using isothermal titration calorimetry. Purified WT Nav1.5 C terminus and FGF13 associated with high affinity ( $K_d = 17$  nM; Table S1; Fig. 2G). In contrast, purified Nav1.5 C terminus p.H1849R showed  $\sim 100$ -fold decrease in affinity for purified FGF13 ( $K_d = 1.9$   $\mu$ M; Table S1; Fig. 2H and I). In summary, Nav1.5 p.H1849R is associated with familial arrhythmias and significantly alters the interaction of Nav1.5 with FHF family proteins.

**Creation of in Vivo Model to Investigate Human SCN5A Variants.** To analyze the consequences of altered interaction between the Nav1.5 p.H1849R variant and FHFs on select  $I_{Na}$  properties, we created a new mouse model for inducible cardiomyocyte Nav1.5 silencing. *Scn5a* knock-in mice were created with *loxP* sites flanking *Scn5a* exons 10 and 13 (Fig. S1) to silence *Scn5a* expression in the presence of *Cre* recombinase. Following birth, cardiomyocytes isolated from neonatal *Scn5a*<sup>fl/fl</sup> mice were cultured and analyzed for

Nav1.5-dependent current  $\pm$  Adv-Cre transduction. Though we observed robust  $I_{Na}$  in mock-transduced myocytes, we detected only negligible  $I_{Na}$  in cultures transduced with Adv-Cre (Fig. S1). Consistent with these data, we observed diminished Nav1.5 by immunoblot and immunostaining of Adv-Cre-infected myocytes (Fig. S1). Despite  $I_{Na}$  loss, myocytes remained healthy and viable. Notably, introduction of exogenous WT Nav1.5 in these cultures resulted in rescue of  $I_{Na}$  to approximately physiological levels (*Scn5a*<sup>fl/fl</sup> myocyte  $I_{Na,peak}$ :  $115.2 \pm 8.4$  pA/pF; *Scn5a*<sup>fl/fl</sup> + Adv-Cre + Nav1.5  $I_{Na,peak}$ :  $142.2 \pm 18.2$  pA/pF). Thus, this new system is sufficient to analyze  $I_{Na}$  properties of putative Nav1.5 variants.

**Nav1.5 p.H1849R Alters Nav1.5 Steady-State Inactivation in Primary Myocytes.** FHF proteins regulate Nav channel steady-state inactivation (21, 29), and knockdown of FHFs in cardiomyocytes results in a hyperpolarizing shift in steady-state interaction (24, 27). We therefore used the *Scn5a*<sup>fl/fl</sup> myocyte system to test the human Nav1.5 H1849R variant for alterations in  $I_{Na}$  inactivation properties. As noted above,  $I_{Na}$  levels in Adv-Cre-infected *Scn5a*<sup>fl/fl</sup> myocytes (GFP-positive) are rescued by expression of exogenous Nav1.5 (Fig. 3A). Of note, expression of Nav1.5 p.H1849R at equivalent levels resulted in an increased  $I_{Na}$  density relative to WT Nav1.5 (Fig. 3A; increased  $\sim 34\%$ ;  $P < 0.05$ ). Further, we observed a significant  $\sim 6.7$ -mV depolarizing shift in the  $V_{1/2}$  of voltage-dependent inactivation of the p.H1849R variant compared with the WT channel ( $-101.2$  vs.  $-107.9$  mV;  $P < 0.05$ ; Fig. 3B). Because FHF knockdown in cardiomyocytes leads to a hyperpolarizing shift in steady-state inactivation, these results suggested that the p.H1849R variant maintains an altered interaction with FHFs despite the reduced affinity noted in binding experiments with the isolated Nav1.5 CT and FHFs (Fig. 2). We observed no difference in voltage dependence of activation of WT Nav1.5 compared with Nav1.5 p.H1849R (Fig. 3B), consistent with the lack of effect of FHFs on Nav1.5



**Fig. 4.**  $\text{Na}_v1.5$  p.H1849R prolongs AP duration and elicits spontaneous activity in murine myocytes. (A and B) Compared with myocytes expressing WT  $\text{Na}_v1.5$ ,  $\text{Na}_v1.5$  p.H1849R-expressing myocytes display increased APD [APD<sub>90</sub>; WT  $\text{Na}_v1.5$ :  $33.1 \pm 6.0$  ms ( $n = 7$  myocytes);  $\text{Na}_v1.5$  p.H1849R:  $70.4 \pm 12.7$  ms ( $n = 7$  myocytes)]. (C and D) Unlike myocytes expressing WT  $\text{Na}_v1.5$  ( $n = 7$ ),  $\text{Na}_v1.5$  H1849R-expressing myocytes displayed spontaneous activity during pacing (myocytes paced at 0.5 Hz in C) or spontaneous depolarizations following pacing [spontaneous activity observed following pause following 10 stimulations (red points) at 1.0 Hz in D].

interaction in cardiomyocytes (24). In summary, consistent with past work linking FHF with regulation of  $\text{Na}_v$  channel steady-state inactivation (21, 24, 27, 29),  $\text{Na}_v1.5$  p.H1849R displays aberrant steady-state inactivation in primary myocytes.

**$\text{Na}_v1.5$  p.H1849R Displays Arrhythmogenic  $I_{\text{Na}}$  Properties.** Patients harboring *SCN5A* variants with LQT3 display signature QT interval prolongation associated with altered  $\text{Na}_v1.5$  regulation. To date, two molecular mechanisms underlying aberrant  $I_{\text{Na}}$  regulation in LQT3 are described. LQT3 is primarily caused by *SCN5A* variants that alter the fast inactivation gate of  $I_{\text{Na}}$ , resulting in channels that may reopen at later stages of the action potential (30). This depolarizing “late”  $I_{\text{Na}}$  current thus extends ventricular depolarization, often resulting in arrhythmogenic afterdepolarizations. Alternatively, human LQT3 may also be linked with *SCN5A* variants that slow  $\text{Na}_v1.5$  channel inactivation (individual channels with longer open state duration) (31, 32), again extending ventricular depolarization and creating a substrate for arrhythmogenic afterdepolarizations.

To identify potential pathogenic mechanisms of the human  $\text{Na}_v1.5$  H1849R variant in the complete absence of any potentially competing ionic currents, we analyzed  $I_{\text{Na}}$  signatures of WT  $\text{Na}_v1.5$  and  $\text{Na}_v1.5$  p.H1849R coexpressed with FGF12 in HEK293 cells (*SI Materials and Methods*). FGF12 was chosen as the FHF for this assay as it is the most abundant FHF in human heart (27). Consistent with findings in myocytes, we observed increased  $I_{\text{Na,peak}}$  for  $\text{Na}_v1.5$  p.H1849R compared with WT  $\text{Na}_v1.5$  (Fig. 3C;  $P < 0.05$ ). Further, we observed a depolarizing shift in steady-state inactivation for  $\text{Na}_v1.5$  p.H1849R compared with WT  $\text{Na}_v1.5$  (Fig. 3D;  $\sim 9$ -mV shift for  $\text{Na}_v1.5$  p.H1849R relative to WT;  $-67.7 \pm 1.9$  vs.  $-76.8 \pm 1.9$  mV, respectively;  $P < 0.05$ ). We did not observe differences in activation between  $\text{Na}_v1.5$  and  $\text{Na}_v1.5$  p.H1849R [Fig. 3E; WT:  $-57.1 \pm 2.5$  mV, p.H1849R:  $-56.0 \pm 1.5$  mV;  $P =$  not significant (N.S.)]. Most notably, we observed a striking slowing of inactivation of  $\text{Na}_v1.5$  p.H1849R

compared with WT  $\text{Na}_v1.5$  (Fig. 3F and G;  $\sim$ fivefold increase in decay time for  $\text{Na}_v1.5$  p.H1849R compared with WT  $\text{Na}_v1.5$ ;  $P < 0.05$ ). In summary, the  $\text{Na}_v1.5$  p.H1849R variant has a number of gain-of-function phenotypes contributing to its arrhythmogenic properties, most notably a slowed rate of inactivation.

**$\text{Na}_v1.5$  H1849R Alters Myocyte Membrane Excitability.** Action potentials (APs) were measured in myocytes expressing WT  $\text{Na}_v1.5$  or  $\text{Na}_v1.5$  p.H1849R to define the relationship between the human variant and myocyte membrane excitability. In line with alterations in  $I_{\text{Na}}$  observed in both myocytes and heterologous cells, we observed a significant increase in AP duration (APD) at 90% repolarization (APD<sub>90</sub>) for myocytes expressing  $\text{Na}_v1.5$  p.H1849R compared with WT  $\text{Na}_v1.5$ -expressing myocytes (Fig. 4A and B;  $P < 0.05$ ). We observed no difference in resting membrane potential or peak transmembrane potential between the two groups ( $P =$  N.S.). Notably, consistent with the significant differences in APD<sub>90</sub>, we observed spontaneous depolarizations (Fig. 4C and D) in  $\text{Na}_v1.5$  p.H1849R myocytes but not in myocytes expressing WT  $\text{Na}_v1.5$  (WT  $\text{Na}_v1.5$ : 0% myocytes;  $\text{Na}_v1.5$  p.H1849R:  $\sim 43\%$  myocytes;  $P < 0.05$ ). In summary, consistent with altered  $I_{\text{Na}}$  and the human LQT3 phenotype,  $\text{Na}_v1.5$  p.H1849R results in APD prolongation and arrhythmogenic spontaneous membrane afterdepolarizations.

## Discussion

Cardiac ion channel dysfunction is tightly linked with congenital human arrhythmias. Though mutations in ion channel pore and gating regions represent the vast majority of pathogenic variants, a second class of arrhythmia variants alter the regulation of ion channels by cytosolic signaling or scaffolding proteins. In fact, these findings have revealed new paradigms for rare forms of human arrhythmia based on defects in ion channel-associated proteins. By integrating human clinical and genetic data with biochemical, cell biological, and electrophysiology findings, we identify a new mechanism for human cardiac  $\text{Na}_v$  channelopathy based on loss of binding to the FHF family of ion channel regulatory proteins. Individuals harboring the  $\text{Na}_v1.5$  p.H1849R variant display LQT3 and AF. Functionally,  $\text{Na}_v1.5$  p.H1849R displays an altered interaction with FHFs, resulting in increased  $I_{\text{Na}}$  peak, increased  $\text{Na}_v1.5$  channel availability and, most critically, slowed inactivation. Together, these parameters provide a rationale for the human cardiac phenotypes. In summary, these new findings directly validate the FHF family of signaling proteins as critical for human cardiac excitability. Further, these data illustrate the likely multifunctional roles of FHF proteins for the regulation of membrane excitability across diverse cell types.

The FHFs have gained significant attention due to their role in regulating  $\text{Na}_v$  and  $\text{Ca}_v$  channels (24, 29, 33–36), as well as their links with human excitable cell disease. In neurons, FHF dysfunction has been linked with aberrant  $I_{\text{Na}}$  phenotypes and human FGF14 variants cause spinocerebellar ataxia 27 (25). Further, the FGF13 locus has been linked with nonspecific forms of X-linked mental retardation (26). Finally, relevant for this study, a missense variant in FGF12 linked with aberrant  $\text{Na}_v1.5$  function was recently associated with Brugada syndrome (27). However, to date, no human  $\text{Na}_v$  channel variants that alter association with FHF proteins have been linked with human disease. Of note, though FGF12–14 all directly associate with  $\text{Na}_v$  channels, each display unique  $\text{Na}_v$  channel regulatory properties that may differentially tune  $\text{Na}_v$  channel expression, trafficking, current density, availability, and/or persistent current ( $I_{\text{Na,L}}$ ), depending on the cell type and  $\text{Na}_v$  channel isoform (29, 33, 34). Given these data, the differences in clinical phenotypes are not surprising, but raise important caveats regarding data interpretation.

The molecular mechanisms underlying human LQT3 may be multifactorial but are generally classified into two categories. The primary mechanism underlying LQT3 is altered  $\text{Na}_v1.5$  fast

inactivation (30). As noted above, in this mechanism, mutant  $\text{Na}_v1.5$  channels display an increased probability for reopening, resulting in inward depolarizing  $I_{\text{Na}}$  during the plateau phase of action potential ( $I_{\text{Na,late}}$ ), lengthening of repolarization, and susceptibility to arrhythmogenic afterdepolarizations. However, though less common, slowed inactivation, resulting in  $\text{Na}_v1.5$  channels with increased time in the open state, may also underlie LQT3 (31, 32). In our study,  $\text{Na}_v1.5$  p.H1849R resulted in increased peak  $I_{\text{Na}}$  and increased  $I_{\text{Na}}$  availability (37, 38), consistent with known roles of FHF in channel gating and/or internalization (21, 29). Most notably, the human  $\text{Na}_v1.5$  p.H1849R variant displayed a striking signature of slow inactivation compared with WT  $\text{Na}_v1.5$ . Consistent with these data, compared with WT  $\text{Na}_v1.5$ , myocytes harboring the  $\text{Na}_v1.5$  p.H1849R displayed increased APD and spontaneous afterdepolarizations even in the absence of adrenergic stimulation. Thus, our findings illustrate that  $\text{Na}_v1.5$  p.H1849R is an  $I_{\text{Na}}$  gain-of-function mutation through the slowing of the rate of inactivation and increasing  $\text{Na}_v1.5$  availability during the AP plateau phase, thus prolonging APD and producing proarrhythmic afterdepolarizations. These findings are consistent with prior reports linking  $I_{\text{Na}}$  slow inactivation and increased availability with both LQT3 (31, 32) and AF (38) as well as LQT associated with  $\alpha 1$  syntrophin gene variants (37).

In summary, our data provide, to our knowledge, the first evidence for human disease based on  $\text{Na}_v$  channel gene variants that block FHF regulation. Our combined data support altered FHF binding as the mechanism for arrhythmia for  $\text{Na}_v1.5$  p.H1849R. Further, recent unbiased structural data identify  $\text{Na}_v1.5$  H1849 as a central residue for  $\text{Na}_v1.5$ /FHF association. Although the endogenous concentrations of FHFs and  $\text{Na}_v$  channel  $\alpha$ -subunits in cardiomyocytes are not known, it is reasonable to assume that an

$\sim 100$ -fold decrease in affinity between the core domain of the FHF and the mutant  $\text{Na}_v1.5$  C-terminal domain (CTD), the key interaction sites identified on each molecule (23), would affect FHF-dependent channel function. This hypothesis is consistent with the previous observation that an affinity-reducing mutation within the FHF core, at the  $\text{Na}_v$  channel interaction site, similarly confers altered  $\text{Na}_v$  channel function in neurons (36). However, we note that this variant may also alter  $\text{Na}_v1.5$  folding and biophysical function independent of, or in conjunction with, FHF-mediated effects. Again, it will be critical in future in vivo experiments to dissect these specific points. In closing, our findings underscore the complexity and heterogeneity in the presentation of congenital arrhythmia, particularly as it relates to  $\text{Na}_v1.5$  and its growing list of regulatory proteins.

## Materials and Methods

Approval for use of human subjects was obtained from the Institutional Review Board of Ohio State University, and subjects provided informed consent. Genomic DNA was extracted from peripheral blood lymphocytes of the proband, proband's sister, mother, niece, and grandmother. A full LQTS genetic panel screened for mutations in 12 known disease-causing genes: *KCNQ1*, *KCNH2*, *SCN5A*, *ANK2*, *KCNE1*, *KCNE2*, *KCNJ2*, *CACNA1C*, *CAV3*, *SCN4B*, *AKAP9*, and *SNTA1*. Sequencing identified a heterozygous A > G nucleotide transition in exon 28 in the *SCN5A* gene, producing a histidine-to-arginine amino acid change at the 1849 residue in the  $\text{Na}_v1.5$  protein.

For animal experiments, animals were handled according to approved protocols and animal welfare regulations of the Institutional Animal Care and Use Committee of The Ohio State University. Detailed descriptions of all materials and methods are provided in *SI Materials and Methods*.

**ACKNOWLEDGMENTS.** Funding for this work was provided by NIH Grants HL114893 (to T.J.H.), HL084583, HL083422, and HL114383 (to P.J.M.), and HL071165 (to G.S.P.); the James S. McDonnell Foundation (T.J.H.); and the American Heart Association (P.J.M.).

- Catterall WA (2012) Voltage-gated sodium channels at 60: Structure, function and pathophysiology. *J Physiol* 590(Pt 11):2577–2589.
- Waxman SG (2007) Channel, neuronal and clinical function in sodium channelopathies: From genotype to phenotype. *Nat Neurosci* 10(4):405–409.
- Bennett PB, Yazawa K, Makita N, George AL, Jr (1995) Molecular mechanism for an inherited cardiac arrhythmia. *Nature* 376(6542):683–685.
- Bendahhou S, Cummins TR, Tawil R, Waxman SG, Ptáček LJ (1999) Activation and inactivation of the voltage-gated sodium channel: Role of segment S5 revealed by a novel hyperkalaemic periodic paralysis mutation. *J Neurosci* 19(12):4762–4771.
- Saito YA, et al. (2009) Sodium channel mutation in irritable bowel syndrome: Evidence for an ion channelopathy. *Am J Physiol Gastrointest Liver Physiol* 296(2):G211–G218.
- Waxman SG, et al. (2014) Sodium channel genes in pain-related disorders: Phenotype-genotype associations and recommendations for clinical use. *Lancet Neurol* 13(11):1152–1160.
- Meisler MH, Kearney JA (2005) Sodium channel mutations in epilepsy and other neurological disorders. *J Clin Invest* 115(8):2010–2017.
- Remme CA (2013) Cardiac sodium channelopathy associated with *SCN5A* mutations: electrophysiological, molecular and genetic aspects. *J Physiol* 591(Pt 17):4099–4116.
- Ptáček LJ, Tawil R, Griggs RC, Storvick D, Leppert M (1992) Linkage of atypical myotonia congenita to a sodium channel locus. *Neurology* 42(2):431–433.
- Wilde AA, Brugada R (2011) Phenotypic manifestations of mutations in the genes encoding subunits of the cardiac sodium channel. *Circ Res* 108(7):884–897.
- Shy D, et al. (2014) PDZ domain-binding motif regulates cardiomyocyte compartment-specific  $\text{Na}_v1.5$  channel expression and function. *Circulation* 130(2):147–160.
- Mohler PJ, et al. (2004)  $\text{Nav}1.5$  E1053K mutation causing Brugada syndrome blocks binding to ankyrin-G and expression of  $\text{Nav}1.5$  on the surface of cardiomyocytes. *Proc Natl Acad Sci USA* 101(50):17533–17538.
- Makara MA, et al. (2014) Ankyrin-G coordinates intercalated disc signaling platform to regulate cardiac excitability in vivo. *Circ Res* 115(11):929–938.
- Spampanato J, et al. (2004) A novel epilepsy mutation in the sodium channel *SCN1A* identifies a cytoplasmic domain for beta subunit interaction. *J Neurosci* 24(44):10022–10034.
- Tan HL, et al. (2002) A calcium sensor in the sodium channel modulates cardiac excitability. *Nature* 415(6870):442–447.
- Aiba T, et al. (2014) A mutation causing Brugada syndrome identifies a mechanism for altered autonomic and oxidant regulation of cardiac sodium currents. *Circ Cardiovasc Genet* 7(3):249–256.
- Koval OM, et al. (2012)  $\text{Ca}^{2+}$ /calmodulin-dependent protein kinase II-based regulation of voltage-gated  $\text{Na}^{+}$  channel in cardiac disease. *Circulation* 126(17):2084–2094.
- Glynn P, et al. (2015) Voltage-gated sodium channel phosphorylation at Ser571 regulates late current, arrhythmia, and cardiac function in vivo. *Circulation* 132(7):567–577.
- Smallwood PM, et al. (1996) Fibroblast growth factor (FGF) homologous factors: New members of the FGF family implicated in nervous system development. *Proc Natl Acad Sci USA* 93(18):9850–9857.
- Liu CJ, Dib-Hajj SD, Waxman SG (2001) Fibroblast growth factor homologous factor 1B binds to the C terminus of the tetrodotoxin-resistant sodium channel rNav1.9a (NaN). *J Biol Chem* 276(22):18925–18933.
- Lou JY, et al. (2005) Fibroblast growth factor 14 is an intracellular modulator of voltage-gated sodium channels. *J Physiol* 569(Pt 1):179–193.
- Laezza F, et al. (2007) The FGF14(F145S) mutation disrupts the interaction of FGF14 with voltage-gated  $\text{Na}^{+}$  channels and impairs neuronal excitability. *J Neurosci* 27(44):12033–12044.
- Wang C, Chung BC, Yan H, Lee SY, Pitt GS (2012) Crystal structure of the ternary complex of a  $\text{Na}_v$  C-terminal domain, a fibroblast growth factor homologous factor, and calmodulin. *Structure* 20(7):1167–1176.
- Wang C, et al. (2011) Fibroblast growth factor homologous factor 13 regulates  $\text{Na}^{+}$  channels and conduction velocity in murine hearts. *Circ Res* 109(7):775–782.
- van Swieten JC, et al. (2003) A mutation in the fibroblast growth factor 14 gene is associated with autosomal dominant cerebellar ataxia [corrected]. *Am J Hum Genet* 72(1):191–199.
- Gez C, et al. (1999) Fibroblast growth factor homologous factor 2 (FHF2): Gene structure, expression and mapping to the Börjeson-Forsman-Lehmann syndrome region in Xq26 delineated by a duplication breakpoint in a BFLS-like patient. *Hum Genet* 104(1):56–63.
- Hennessey JA, et al. (2013) FGF12 is a candidate Brugada syndrome locus. *Heart Rhythm* 10(12):1886–1894.
- Goldfarb M, et al. (2007) Fibroblast growth factor homologous factors control neuronal excitability through modulation of voltage-gated sodium channels. *Neuron* 55(3):449–463.
- Laezza F, et al. (2009) FGF14 N-terminal splice variants differentially modulate  $\text{Nav}1.2$  and  $\text{Nav}1.6$ -encoded sodium channels. *Mol Cell Neurosci* 42(2):90–101.
- Wang DW, Yazawa K, George AL, Jr, Bennett PB (1996) Characterization of human cardiac  $\text{Na}^{+}$  channel mutations in the congenital long QT syndrome. *Proc Natl Acad Sci USA* 93(23):13200–13205.
- Wedekind H, et al. (2001) De novo mutation in the *SCN5A* gene associated with early onset of sudden infant death. *Circulation* 104(10):1158–1164.
- Kambouris NG, et al. (1998) Phenotypic characterization of a novel long-QT syndrome mutation (R1623Q) in the cardiac sodium channel. *Circulation* 97(7):640–644.
- Rush AM, et al. (2006) Differential modulation of sodium channel  $\text{Na}_v1.6$  by two members of the fibroblast growth factor homologous factor 2 subfamily. *Eur J Neurosci* 23(10):2551–2562.
- Wittmack EK, et al. (2004) Fibroblast growth factor homologous factor 2B: Association with  $\text{Nav}1.6$  and selective colocalization at nodes of Ranvier of dorsal root axons. *J Neurosci* 24(30):6765–6775.
- Hennessey JA, Wei EQ, Pitt GS (2013) Fibroblast growth factor homologous factors modulate cardiac calcium channels. *Circ Res* 113(4):381–388.
- Yan H, Pablo JL, Wang C, Pitt GS (2014) FGF14 modulates resurgent sodium current in mouse cerebellar Purkinje neurons. *eLife* 3:e04193.
- Wu G, et al. (2008)  $\alpha$ -1-syntrophin mutation and the long-QT syndrome: A disease of sodium channel disruption. *Circ Arrhythm Electrophysiol* 1(3):193–201.
- Makiyama T, et al. (2008) A novel *SCN5A* gain-of-function mutation M1875T associated with familial atrial fibrillation. *J Am Coll Cardiol* 52(16):1326–1334.